Live webcast on Thursday, May 29th at 2:20 PM ET BOSTON and LONDON – May 22, 2025 – Akari Therapeutics, Plc …
PRESS RELEASES
Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Advancing development of novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads to treat multiple cancer tumors Rounding out executive team with …
Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development – Oncology
Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products Successful track record …
